L-ergothioneine, milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage

ABSTRACT

This invention provides therapeutic compositions and combinations for the protection, treatment and repair of liver tissue. The invention relates to novel compositions and combinations comprising two or more compounds selected from the group consisting of S-adenosylmethionine, L-ergothioneine, and a substance selected from the group consisting of constituents of Milk thistle ( Silybum marianum ), silymarin and active components of silymarin, whether naturally, synthetically, or semi-synthetically derived, and to methods of preventing and treating liver disease and of repairing damaged liver tissue. The invention also provides a method of administering these compositions and combinations to humans or animals in need thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of U.S. patentapplication Ser. No. 10/153,877, filed May 24, 2002, now U.S. Pat. No.6,863,906, which is a continuation of U.S. patent application Ser. No.09/731,719, filed Dec. 8, 2000, now abandoned, which is acontinuation-in-part application of U.S. patent application Ser. No.09/256,352, filed Feb. 24, 1999, now U.S. Pat. No. 6,555,141, thedisclosures of which are hereby incorporated by reference herein intheir entirety. That application claimed priority to provisionalapplication: “L-ER.GOTHIONEINE, MILK THISTLE, AND S-ADENOSYLMETHIONINEFOR LIVER FAILURE,” U.S. Ser. No. 60/076,347, filed Feb. 27, 1998, thedisclosure of which is hereby incorporated by reference herein in itsentirety.

FIELD OF THE INVENTION

The present invention relates to compositions and combinations for theprotection, treatment and repair of liver tissues in humans and animals.

BACKGROUND OF THE INVENTION

The liver is an extremely important organ. As the major metabolic organof the body, the liver plays some role in almost every biochemicalprocess, including the deamination of amino acids and the formation ofurea, the regulation of blood sugar through the formation of glycogen,the production of plasma proteins, the production and secretion of bile,phagocytosis of particulate matter from the splanchnic (intestinal)circulation, and the detoxification and elimination of both endogenousand exogenous toxins.

The many functions of the liver depend on its intimate association withcirculating blood. Each liver cell is exposed on at least one face to ablood sinusoid which contains oxygenated arterial blood mixed withvenous blood from the splanchnic circulation. This profuse blood supplyis necessary for the liver to function. The blood from the sinusoidssupplies the hepatocytes with oxygen and nutrients. The hepatocytes usethe nutrients both for their own metabolic needs and for the synthesisof the liver's many essential products. Abnormalities in the blood orvasculature can have immediate and severe effects on the liver. Forexample, liver cells are exposed to high concentrations of any toxiccompounds that are ingested orally, such as ethyl alcohol. Even when theingested compound is not itself toxic, intermediate derivatives producedduring hepatic metabolism of the compound may damage the hepatocytes.This phenomenon occurs, for example, in carbon tetrachloride poisoning.Since the blood moves slowly through hepatic sinusoids, liver cells arealso quite vulnerable to blood-borne infectious agents such as virusesand bacteria. Furthermore, derangements in hepatic blood pressure candamage liver tissue. Right-sided cardiac failure increases hepatic bloodpressure and can lead to pressure necrosis (hepatocellular death) andfibrosis. Left-sided cardiac failure can reduce hepatic perfusion andlead to hepatocellular anoxia and death.

Liver damage from any source may result in liver regeneration, necrosis(cell death), degeneration, inflammation, fibrosis, or mixtures of theseprocesses, depending on the type and extent of injury and its locationwithin the liver. The liver has great functional reserves, but withprogressive injury, disruption of liver function can havelife-threatening consequences. Cirrhosis, which is a type of end-stageliver disease, is one of the top ten causes of death in the Westernworld.

Despite the significance and potential severity of liver disease,therapeutic approaches are limited. Treatment is generally symptomatic,e.g., the use of diuretics to combat tissue edema caused by low levelsof plasma proteins. Many types of liver disease are the result ofviruses (e.g., hepatitis A, B, C, D and E, to name a few), and effectiveantiviral therapies are rare and commonly cause potentially severe sideeffects. Other liver diseases are the result of previous toxic exposure(such as alcoholic cirrhosis and exposure to toxic plants, orenvironmental pollutants) which may be difficult to control. In stillother cases, liver disease is the result of poorly understood interplayof various factors, including genetic factors, environmental conditions,and immune system activity (autoimmune hepatitis). These cases are, in aword, idiopathic, and as such are difficult to treat exceptsymptomatically. In short, due in part to the complexity of liverdisease, therapies do not currently exist that address its causes. Nordoes there currently exist a therapy that supports normal liver functionand helps heal damaged liver tissue. Currently available therapieseither focus only on the secondary symptoms of liver disease or havesignificant side effects, as is the case with antiviral drugs. There isa need for a therapeutic composition that will support liver structure,function and healing, with few or no side effects.

SUMMARY OF THE INVENTION

The present invention provides compositions and combinations for theprotection, treatment and repair of liver tissue in humans and animals.

Additionally, the present invention provides such compositions andcombinations that also produce a low level of side effects.

The present invention also provides a method of using the novelcompositions and combinations of the present invention to protect, treator repair liver tissue in humans or animals in need thereof.

The present invention provides novel compositions, combinations andmethods for protecting, treating and repairing liver tissue. Thecompositions and combinations of the invention include two or more ofthe following compounds: S-adenosylmethionine, L-ergothioneine and asubstance selected from the group consisting of a constituent of Milkthistle, silymarin and active components of silymarin, whethernaturally, synthetically, or semi-synthetically derived.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the molecular structure of S-adenosylmethionine.

FIG. 2 diagrams the major metabolic pathways of S-adenosylmethionine inthe body.

FIG. 3 diagrams the effects of ethanol in the hepatocyte.

FIG. 4 is the molecular structure of L-ergothioneine.

FIG. 5 shows the effect of ergothioneine and other compounds on lipidperoxide formation in mouse liver homogenate.

FIG. 6 is a drawing of the herb Milk thistle (Silybum marianun).

FIG. 7 is the molecular structures of silybin and other compounds fromMilk thistle.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the teachings of the present invention, disclosedherein are compositions, combinations and methods for the protection,treatment and repair of liver tissue. The invention relates to novelcompositions and combinations comprising two or more compounds selectedfrom the group consisting of S-adenosylmethionine, L-ergothioneine, anda substance selected from the group consisting of constituents of Milkthistle (Silybum marianum), silymarin and active components ofsilymarin, whether naturally, synthetically, or semi-syntheticallyderived, and to methods of preventing and treating liver disease and ofrepairing damaged liver tissue.

S-adenosylmethionine (“SAMe”) (FIG. 1) is a significant physiologiccompound that is present throughout body tissue and that takes part in anumber of biologic reactions as a methyl group donor or an enzymaticactivator during the synthesis and metabolism of hormones,neurotransmitters, nucleic acids, phospholipids, and proteins. It isnaturally formed in the body from ATP and methionine. SAMe is anextremely important reactant in many biochemical reactions includingtransmethylation, transsulfation, and synthesis of amines (FIG. 2).Stramentinoli, G., Pharmacologic Aspects of S-Adenosylmethionine,American Journal of Medicine 83 (5A), 1987, pp. 35-42. In higherorganisms, SAMe plays a significant role in transmethylation processesin more than 40 anabolic or catabolic reactions involving the transferof the methyl group of SAMe to substrates such as nucleic acids,proteins and lipids, among others. The release of the methyl group fromSAMe is also the start of a “transsulfuration” pathway that produces allendogenous sulfur compounds. After donating its methyl group, SAMe isconverted into S-adenosylhomocysteine, which in turn is hydrolyzed toadenosine and homocysteine. The amino acid cysteine may then be producedfrom the homocysteine. Cysteine may exert a reducing effect by itself oras an active part of glutathione, which is a main cell antioxidant. Id.SAMe additionally has anti-oxidant effects via its derivatives (e.g.,methylthioadenosine), which prevent oxidative damage to ells.Glutathione itself is a product of SAMe via the transmethylation andtranssulfation pathways.

SAMe and its products, including glutathione, are of great importance inthe prevention of liver damage. The changes produced by ethanol (EtOH)in the liver provide examples of injuries that can occur in the liver onthe cellular level (FIG. 3), and help explain the mechanism of action bywhich SAMe counteracts these injuries.

EtOH absorbed in the blood stream is metabolized in the liver by theenzyme alcohol dehydrogenase. This reaction releases excessnicotinamide-adenine-dinucleotide (NADH) which in turn shunts substrates(carbohydrates, lipids, and proteins) in the liver away from normalcatabolic processes and towards lipid biosynthesis. As lipids accumulatein the liver cells in the form of large droplets, organelles arephysically displaced and crowded, and this phenomenon decreases thecells' ability to function. Secondly, alcohol induces the P 450 systemof cytochromes, and the microsomal ethanol oxidizing system (“MEOS”)within liver cells, leading to augmented transformation of variouscompounds in the body (including, for example, chemicals from tobaccosmoke) into toxic metabolites, and producing free radicals. Becausealcohol consumption decreases glutathione pools, damage already producedby these free radicals is exacerbated. Alcohol and its metabolites(e.g., acetaldehyde) also interact with phospholipids and therefore havedirect effects on hepatocellular membranes, decreasing their fluidityand affecting the function of organelles such as mitochondria andendoplasmic reticulum. Finally, acetaldehyde alters hepatocellularproteins, including the sodium/potassium pump, decreasing the ability ofthese proteins to function. The sodium/potassium pump is amembrane-bound protein that is responsible for maintaining the balanceof sodium and potassium across the cell membrane of every cell in thebody. Because many cell functions depend on the electrochemical gradientthat results from this distribution of sodium and potassium, thesodium/potassium pump is essential to enable cells to perform. Livercells are no exception. The alterations in proteins that alcohol and itsmetabolites induce also have the effect of making these proteins more‘foreign’ and thus more likely to induce autoimmune reactions. In short,alcohol damages the liver in a myriad of ways. FIG. 3; Lieber, C.,Biochemical factors in alcoholic liver disease, Seminars in LiverDisease, 13 (2), 1993, pp. 136-53.

SAMe has a variety of beneficial effects in cells and protectshepatocytes from these injurious influences in a number of differentways. For example, SAMe has been shown to decrease lipid accumulation inrats chronically intoxicated with ethanol. This effect is not completelyunderstood, but is partially explained by SAMe's ability to inhibitalcohol dehydrogenase. This single function of SAMe in itself preventsnot only lipid accumulation but also much of the additional damageacetaldehyde causes to cellular membranes and proteins. Pascale, R., etal., Inhibition by ethanol of rat liver plasma membrane (Na+ K+)ATPase:protective effect of SAMe, L-methionine, and N-acetylcysteine,Toxicology and Applied Pharmacology, 97, 1989, pp. 216-29. Furthermore,because SAMe catalyses the transformation of phosphatidylethanolamine tophosphatidylcholine, it supports the normal fluidity of cell membranes,thereby supporting the structure and function of organelles includingthe plasma membrane, mitochondria and endoplasmic reticulum. Thissupportive effect avoids many of alcohol's damaging secondary effects.Bevi B., et al., Protection of rat fetal hepatocytes membranes fromethanol mediated cell injury and growth impairment, Hepatology 16, 1992,p. 109A.

SAMe also protects liver cells indirectly via its antioxidant productscysteine and glutathione, which help prevent damage by the excessivefree radicals produced during alcohol intoxication. Pascale R., et al.,The role of SAMe in the regulation of glutathione pool and acetaldehydeproduction in acute ethanol intoxication, Research Communications inSubstances of Abuse, Vol. 5, No. 4, 1984, pp. 321-24.

Laboratory animal studies and in vitro experiments have verified theseeffects of SAMe on the inner, lipid layer of the plasma membrane. Champ,P. and Harvey, R., Biochemistry, 2^(nd) ed., Lippincott, Philadelphia,1994, pp. 266-7; Stramentinoli, G., Pharmacologic aspects of SAMe,American Journal of Medicine, Vol. 83 (5A) 1987, p. 35; Baldessarini,F., Neuropharmacology of S-Adenosyl Methionine, American Journal ofMedicine 83 (5A), 1987, p. 95; Carney, M., Neuropharmacology ofS-Adenosyl Methionine, Clinical Neuropharmacology 9 (3), 1986, p. 235;Janicak, P., S-Adenosylmethionine in Depression, Alabama Journal ofMedical Sciences 25 (3), 1988, p. 306.

SAMe has been used to treat various disorders. In certain forms of liverdisease, SAMe acts as an anticholestatic agent. Adachi, Y., et al., TheEffects of S-adenosylmethionine on Intrahepatic Cholestasis, Japan Arch.Inter. Med., 33 (6), 1986, pp. 185-92. One mechanism by which SAMeexerts this effect is via its ability to maximize membrane fluidity,which is a crucial factor in the secretion of bile acids fromhepatocytes. Id. Another mechanism is via the transsulfation pathway andthe production of sulfates and taurine, which are important inmobilization of bile acids. Frezza, M., The use of SAMe in the treatmentof cholestatic disorders, Drug Investigation, 4 (Suppl. 4), 1992, pp.101-08. Low levels of SAMe are believed to play a role in increasing therisk of certain cancers. Feo F., et al., Early Stimulation of PolyamineBiosynthesis During Promotion by Phenobarbital ofDiethylnitrosamine-induced Rat Liver Carcinogenesis. The Effects ofVariations of the S-adenosyl-L-methionine Cellular Pool, Carcinogenesis,6 (12), 1985, pp. 1713-20. The administration of SAMe has also beenassociated with a fall in the amount of early reversible nodules and theprevention of the development of late pre-neoplastic lesions andhepatocellular carcinomas. Garcea, R., et al., Variations of OrnithineDecarboxylase Activity and S-adenosyl-L-methionine and5′-methylthioadenosine Contents During the Development ofDiethylnitrosamine-induced Liver Hyperplastic Nodules and HepatocellularCarcinoma, Carcinogenesis, 8 (5), 1987, pp. 653-58. SAMe is avaliable inmany different salt forms as would be known by a person of ordinaryskill in the art, any of which, or any combination of which, would beuseful in the invention. SAMe and its salt forms may be natural,semisynthetic, bioengineered, synthetic or extracted, any of which, orany combination of which, would be useful in the invention.

L-ergothioneine (FIG. 4) is a naturally occurring antioxidant that isvery stable in the body. It is synthesized in fungi and microorganismsand present in both plants and animals. Animals are unable to synthesizeL-ergothioneine and must obtain it from dietary sources. It is readilyabsorbed and is active in most mammalian tissues, concentratingespecially in the liver, where it prevents certain types offree-radical-induced damage to cell membranes and organelles. Forexample, exogenous L-ergothioneine has been shown to prevent lipidperoxidation by toxic compounds in the liver tissue of rats. Akanmu, D.,et al., The antioxidant action of ergothioneine, Arch. of Biochemistryand Biophysics, 288 (1), 1991, pp. 10-16; Kawano, H., et al., Studies onErgothioneine: Inhibitory effect on lipid peroxide formation in mouseliver, Chem. Pharm. Bull., 31 (5), 1983, pp. 1662-87. In study comparingthe inhibition of lipid peroxide (“LPO”) formation by various compoundsin mouse liver, L-ergothioneine both inhibited LPO formation andenhanced the decomposition of existing LPO (FIG. 5). Id. L-ergothioneineadditionally has been shown to inhibit the damaging effects caused bythe oxidation of iron-containing compounds, such as hemoglobin andmyoglobin. These molecules are important in the body as carriers ofoxygen, but because they contain divalent iron, they can interact withhydrogen peroxide via the Fenton reaction to produce the even moredamaging hydroxyl radical. This is the mechanism by which damage occursduring so-called reperfusion injury. Because L-ergothioneine acts as areducing agent of the ferryl-myoglobin molecule, it can protect tissuesfrom reperfusion injury. Hanlon, D., Interaction of ergothioneine withmetal ions and metalloenzymes, J. Med. Chem., 14 (11), 1971, pp.1084-87. Although L-ergothioneine does not directly scavenge superoxideanion or hydrogen peroxide, it contributes to the control of these freeradicals by participating in the activation of superoxide dismutase andglutathione peroxidase. Its protective effects on cell membranes andother organelles are of benefit in acute and chronic toxicity as well asin infectious diseases, because common pathogenic biomechanisms areactive in both of these processes. Ergothionine in any form would beuseful in the invention, including natural, semisynthetic,bioengineered, synthetic, extracted and combinations thereof andincluding any other active forms, such as racemic mixtures (D & Lforms). Because ergothioneine is available in nature, it is expectedthat daily microgram amounts will be effective as an antioxidant. Otherantioxidants, such as selenium, are known to be effective asantioxidants at these very low levels.

Milk thistle (Silybum marianum) (FIG. 6), which is also commonly knownas Marian thistle, St. Mary's thistle, and Our Lady's thistle, is anative to the Mediterranean region, but has been naturalized inCalifornia and the eastern United States. This tall herb with pricklyvariegated leaves and milky sap has been used as a folk remedy for liverand biliary complaints for many years and recent research has supportedsuch medicinal use. Foster, S., A Field Guide to Medicinal Plants,Houghton Mifflin Co, Boston, 1990, p. 198. Research over the past 20years has documented that the plant contains a compound referred to assilymarin, which actually consists of various forms of hepatoprotectantflavonolignans. The principal components are silybin (which is alsocalled silybinin); silychristin; and silydianin (which is also calledsilymonin); the 3-deoxy-derivatives of silychristin and silydianin; aswell as isosilychristin; isosilybin (which is also known asisosilybinin) and its 3-deoxy derivative silandrin; the 3-deoxycompounds silyhermin A and B; 2,3 dehydrosilybin; and the trimers,quatramers and pentamers of silybin (which collectively are referred toas silybinomers). Other flavanolignans may be included as well. Isomersof silybin (or silybinin) are silybin A and B (or silybinin A and B).For purposes of this application, the term, “silybin” shall be used, butshall include silybinin. The structure of some of these are illustratedin: (FIG. 7). Tyler, V., The Honest Herbal, Haworth Press, Inc., NewYork, 1993, pp. 209-10; Wichtl, M. (Grainger Bisset, N, trans.), HerbalDrugs and Phytopharmaceuticals, CRC Press, Boca Raton, 1994, pp. 121,124, 125. These hepatoprotectant flavonolignans are referred to in thisapplication as “active components of silymarin.” The fruits (oftenerroneously referred to as the “seeds”) of the plant, for example,contain approximately 3% flavonolignans on average. Laboratory trials inanimals have shown that silymarins protect liver tissue against avariety of toxins including those of the deadly amanita mushrooms andcarbon tetrachloride. Prophylactic effects were especially pronounced.Milk thistle is usually available as an extract that contains silymarin,but it is envisioned that any form or formulation of Milk thistle, e.g.,extract, precipitate, or powdered form, which contains either silymarinor one or more active components of silymarin, would function in thepresent invention. In a preferred embodiment of the invention, the Milkthistle component or components may be “standardized,” i.e., formulatedso that a certain percentage or amount of a specific substance or ofspecific substances is or are present. As an example, the Milk thistlecomponent of the invention (i.e. silymarin and the principal activecomponents of silymarin, such as silybin, silydianin and silychristin)could be an extract. In that case, the extract can be standardized withrespect to the percentage by weight of any or all of the silymarinconstituents, particularly the silybin fractions present in the extract.For example, silymarin may be present in the extract in an amount fromabout 55% to about 85% by weight of the extract. In a more preferredembodiment, silymarin may be standardized so that it is present in anamount from about 67.5% to about 72.5% by weight of the extract. Inanother preferred embodiment the extract can be standardized to theamount of Silybinin A and Silybinin B, which may be present in acombined amount from about 20% to about 35% by weight, and mostpreferably about 28% by weight of the extract. In a still furtherpreferred embodiment, Isosilybin A (also known as Isosilybinin A) andIsosilybin B (also known as Isosilybinin B) may be present in a combinedamount from about 20% to about 35% by weight of the extract, as measuredby HPLC (high pressure liquid chromatography). It may be possible tostandardize the extract with respect to other flavonolignan fractions orisomers, such as dehydrosilybin, silydianin and silycristin, as well astheir 3-deoxy derivatives. Each of these preferred embodiments may bepresent alone or in any combination. Recently, it has been shown thatoral absorption of silymarin can be increased by combining the silimarinwith phosphatidylcholine and this combination may also be used in thepresent invention.

Silymarin and the active components of silymarin have several mechanismsof action, including stimulation of nucleolar polymerase A. Thisstimulation in turn increases ribosomal activity leading to increasedsynthesis of cellular proteins, and an increased rate of hepatocellularrepair. Conti, M., et al., Protective activity ofsilipide on liverdamage in rodents, Japan J. Pharmacol., 60, 1992, pp. 315-21. Otherprotective mechanisms involve changes in the molecular structure of thehepatocellular membrane, which reduce binding and entry of toxins intothe cell, and an antioxidant effect. Parish, R. & Doering, P., Treatmentof Amanita mushroom poisoning: a review, Vet. Hum. Toxocol., 28 (4)1986, pp. 318-22. It is expected that elements of the combinations ofthe present invention will work synergistically together because theyhave different, but complementary, mechanisms of action. Because liverdiseases involve a complex interplay of numerous factors, the exactnature of which may remain obscure to the diagnosing clinician, there isa need for a composition that will address numerous mechanisms of liverdamage. Treating the causative agent may not be—and in liver diseaserarely is—possible. Addressing and preventing hepatic injuries on thecellular level therefore frequently will be the best treatment possibleand almost as beneficial. The present invention combinesantiinflammatory, anti-lipid, anti-necrotic, regenerating, andanti-fibrotic effects. All three ingredients that may be included incompositions of the present invention, S-adenosylmethionine,L-ergothioneine and a compound selected from the group consisting ofMilk thistle, silymarin and active components of silymarin, have stronganti-inflammatory effects because of their antioxidant properties.Because different antioxidants have their primary effect on differentfree radicals, (for example, superoxide dismutase scavenges primarilysuperoxide anion), and because several types of free radicals areimplicated in liver damage, supplying just one antioxidant would onlyaddress one subset of liver-damaging free radicals. It would also have adirect protective effect on protecting the hepatic cells when cells arestimulated by SAMe and or Silymarin to increase protein synthesis asthis action of increased cell metabolism generates free radicals whichcan be neutralized by ergothionine.

Combining two of the three compounds will produce a beneficial effect ina number of liver diseases, and combining all three compounds will helptreat or prevent an extremely broad range of such diseases. Thus, thecompositions and combinations of the present invention will improve andmaintain the health of liver tissue and normalize and improve thefunction of the liver in humans and animals. The combination will alsoallow beneficial effects to be achieved using lower doses than wouldotherwise be necessary. The use of lowered doses is both economicallyadvantageous and reduces the risk of any potential side effects.Although the present ingredients are remarkably free of side effects, nocompound is completely innocuous and giving the lowest effective dose isalways sound medical policy.

The compositions and combinations of the present invention can beadministered by a variety of routes including, but not limited to:orally, parentally, transdermally, sublingually, intravenously,intramuscularly, rectally and subcutaneously. Preferred daily doses forcach of the compounds are as follows. As would be apparent to a personof ordinary skill in the art, these dose ranges are approximations:

SAMe

Total dose range: about 5 mg—about 10 grams

Preferred small animal dose range: about 5 mg—about 1600 mg

Preferred human dose range: about 20 mg—about 5000 mg

Preferred large animal dose range: about 100 mg—about 10 grams

Alternatively, the daily per kilogram dose range of SAMe for all speciesis: about 2 mg/kg—about 100 mg/kg

-   -   L-ergothioneine    -   Total dose range: about 5 μg—about 25 grams    -   Preferred small animal dose range: about 5 μg—about 5 grams    -   Preferred human dose range: about 25 μg—about 10 grams    -   Preferred large animal dose range: about 100 μg—about 25 grams    -   Alternatively, the daily per kilogram dose range of        L-ergothionine for all species is: about 2 μg/kg—about 250 mg/kg    -   Constituent of Milk thistle or silymarin, or active components        of silymarin, (i.e., silybin, isosilybin, etc.)    -   Total dose range: about 5 mg—about 10 grams    -   Preferred small animal dose range: about 5 mg—about 1000 mg    -   Preferred human dose range: about 100 mg—about 5 grams    -   Preferred large animal dose range: about 250 mg—about 10 grams    -   Alternatively, the daily per kilogram dose range of a consituent        of Milk thistle, silymarin, or active components of silymarin        for all species is: about 1 mg/kg—about 200 mg/kg

The daily doses recited above for all compounds may be given in a singledose or divided doses, to be administered, for example, twice-a-day,three-times a day or four-times-a-day. Therefore, the range for a singledose of the components of the invention is as follows:

-   -   SAMe    -   Total single dose range: about 1.25 mg—about 10 grams    -   Preferred small animal single dose range: about 1.25 mg—about        1600 mg    -   Preferred human single dose range: about 5 mg—about 5000 mg    -   Preferred large animal single dose range: about 25 mg—about 10        grams    -   Alternatively, the per kilogram single dose range of SAMe for        all species is: about 0.5 mg/kg—about 100 mg/kg    -   L-ergothioneine    -   Total single dose range: about 1.25 μg—about 25 grams    -   Preferred small animal single dose range: about 1.25 μg—about 5        grams    -   Preferred human single dose range: about 6.25 μg—about 10 grams    -   Preferred large animal single dose range: about 25 μg—about 25        grams    -   Alternatively, the per kilogram single dose range for all        species is: about 0.5 μg/kg—about 250 mg/kg    -   Constituent of Milk thistle (or silymarin, or active components        of silymarin, ie., silybin, isosilybin, etc.)    -   Total single dose range: about 1.25 mg—about 10 grams    -   Preferred small animal single dose range: about 1.25 mg—about        1000 mg    -   Preferred human single dose range: about 25 mg—about 5 grams    -   Preferred large animal single dose range: about 62.5 mg—about 10        grams    -   Alternatively, the per kilogram single dose range of a        constituent of Milk thistle, silymarin, or active components of        silymarin for all species is: about 0.25 mg/kg—about 200 mg/kg

Moreover, the dose may be administered in various combinations in whichthe components may be present in a single dosage form or in more thanone dosage form. For example, the combinations of the present inventionmay be administered in a single daily dosage form in which allcomponents are present, e.g., in a single capsule or tablet. The dosesmay also be administered in combinations of more than one dosage form inwhich each dosage form contains at least one component or in which twoor more components are combined into a single dosage form. For example,a combination of SAMe and ergothioneine may be administered as a pill,capsule or tablet of SAMe and a separate pill, tablet or capsule ofergothioneine. A combination of ergothioneine, SAMe and silymarin mayinclude each component in a separate dosage form, or two of thecomponents in one dosage form, such as combined in the same capsule andthe other component in a separate dosage form, or, as explained above,all three of the components in the same (i.e., a single) dosage form.These combinations may be provided in kits or blister packs, in whichmore than one dosage form of the various components are provided in thesame package or container, for co-administration to a human or animal.For example, a tablet of SAMe and a capsule of silymarin can be placedin the same blister pack for co-administration. These combinations maybe provided, for example, in kits, blister packs, packets or bottlesshrink-wrapped together in which more than one dosage form of thevarious components are provided in the same dispensing unit forcoadministration to a human or animal.

Having discussed the composition of the present invention, it will bemore clearly perceived and better understood from the following specificexamples which are intended to provide examples of the preferredembodiments and do not limit the present invention. Moreover, as statedabove, the preferred components described in these examples may bereplaced by or supplemented with the any of the components of thecompositions of the invention described above.

EXAMPLE 1

A 10-year-old female spayed domestic cat is diagnosed with felineidiopathic hepatic lipidosis (fatty liver). This disease ischaracterized by the accumulation of triglycerides within the cytoplasmof liver cells. The cells become so swollen with lipids that they ceaseto function, and many die (hepatic necrosis). The cellular swelling alsoinhibits blood flow in hepatic sinusoids, compounding the damage withpoor perfusion. Symptoms of the disease include loss of appetite,vomiting, depression and CNS signs (hepatic encephalopathy). Since thecause of this disease is unknown, it is currently treatedsymptomatically. Even with aggressive treatment, 40 to 50% of affectedanimals succumb. In this case, in addition to symptomatic treatment(tube feeding, fluids, pharmacologic control of vomiting), the patientis given daily a mixture of 100 mg SAMe, 100 mg silymarin, and 100 mg ofL-ergothionine until appetite returns. The SAMe and silymarin supportrepair of damaged hepatocytes and their function, the production ofenzymes and other proteins. The L-ergothioneine prevents reperfusioninjury. The net result is that the cat recovers, and the rate ofrecovery is increased so that the cat spends fewer days hospitalized.

EXAMPLE 2

A farmer in Lancaster County, Pennsylvania, reports that one of his cowshas died in convulsions and that several sheep and a pig in the samepasture are also sick. Poisoning by cocklebur plants (Xanthiumstrumarium) is diagnosed. In this condition, a toxin produced by theplant causes fatty change, swelling, and death in liver cells. Animalsthat survive the initial illness may develop chronic liver disease.Currently, the only method of treatment is removal of the plant from thediet. In this case, the pigs and sheep are removed from the pasture andadministered daily SAMe (5 mg/kg), silymarin (40 mg/kg), andL-ergothioneine (100 mg per animal) for one to two weeks. The SAMe helpsmaintain cellular membranes and the Na/K/ATPase pump, which are thecellular organelles most likely to be damaged by the toxin. Thesilymarin stimulates synthesis of replacement proteins and theL-ergothioneine prevents reperfusion injury.

EXAMPLE 3

A 58-year-old man has osteoarthritis. To control the pain in his joints,he takes large amounts of the drug acetaminophen. Like many other drugs,acetaminophen can cause hepatic damage by decreasing glutathione levels.This patient wishes to continue to take acetaminophen, becausenonsteroidal anti-inflammatory drugs cause unacceptable gastrointestinalirritation. In this case, the patient continues to take acetaminophen,but also takes SAMe 200 mg, and L-ergothioneine 100 mg daily as long ashe continues to take acetaminophen. The SAMe increases hepaticglutathione levels, and the L-ergothioneine ensures maximum effect ofthe available glutathione via glutathione peroxidase activation. The netresult is that liver structure and function are supported in the face ofan ongoing potentially hepatotoxic exposure.

Many modifications may be made without departing from the basic spiritof the present invention. Accordingly, it will be appreciated by thoseskilled in the art that within the scope of the appended claims, theinvention may be practiced other than has been specifically describedherein. Hence, the attached claims are intended to cover the inventionembodied in the claims and substantial equivalents thereto.

1. A composition comprising S-adenosylmethionine and a substanceselected from the group consisting of silymarin and active components ofsilymarin.
 2. The composition of claim 1, wherein the substancecomprises silybin.
 3. The composition of claims 1 or 2, furthercomprising phosphatidylcholine.
 4. The composition of claim 3, whereinthe substance comprises silymarin.
 5. The composition of claim 3,wherein a single dose of the S-adenosylmethionine ranges from about 1.25milligrams to about 10 grams.
 6. The composition of claim 3, wherein asingle dose of the S-adenosylmethionine for administration to a smallanimal ranges from about 1.25 milligrams to about 1600 milligrams. 7.The composition of claim 3, wherein a single dose of theS-adenosylmethionine for administration to a human ranges from about 5milligrams to about 5000 milligrams.
 8. The composition of claim 3,wherein a single dose of the S-adenosylmethionine for administration toa large animal ranges from about 25 milligrams to about 10 grams.
 9. Thecomposition of claim 3, wherein a single dose of theS-adenosylmethionine ranges from about 0.5 milligrams per kilogram toabout 100 milligrams per kilogram.
 10. The composition of claim 3,wherein the substance comprises silybin, and wherein a single dose ofthe silybin ranges from about 1.25 milligrams to about 10 grams.
 11. Thecomposition of claim 3, wherein the substance comprises silybin, andwherein a single dose of the silybin ranges from about 0.25 milligramsper kilogram to about 200 milligrams per kilogram.
 12. The compositionof claim 3, wherein the substance comprises silybin, and wherein asingle dose of the silybin for administration to a small animal rangesfrom about 1.25 milligrams to about 1000 milligrams.
 13. The compositionof claim 3, wherein the substance comprises silybin, and wherein asingle dose of the silybin for administration to a human ranges fromabout 25 mg to about 5 grams.
 14. The composition of claim 3, whereinthe substance comprises silybin, and wherein a single dose of thesilybin for administration to a large animal ranges from about 62.5milligrams to about 10 grams.
 15. The composition of claim 3, whereinthe substance is standardized such that silymarin is present in thesubstance in an amount from about 55% to about 85% by weight of thesubstance.
 16. The composition of claim 15, wherein the substancecomprises silymarin in an amount from about 67.5% to about 72.5% byweight of the substance.
 17. The composition of claim 3, wherein thesubstance is standardized such that Silybin A and Silybin B are presentin the substance in a combined amount from about 20% to about 35% byweight of the substance.
 18. The composition of claim 3, wherein SilybinA and Silybin B are present in the substance in a combined amount ofabout 28% by weight of the substance.
 19. The composition of claim 3,wherein the substance is standardized such that Isosilybin A andIsosilybin B are present in the substance in a combined amount fromabout 20% to about 35% by weight of the substance.